Form 4 for IMNM Immunome Inc.
Accepted 2026-04-03 19:46:52 ET · period of report 2026-04-02 · accession 0001994071-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-03 19:46 | 2026-04-02 | IMNM | Rosett Max | CFO | M - OptEx | $1.22 | +71.6K | 119.0K | +151% | +$87.1K |
| DMT | 2026-04-03 19:46 | 2026-04-02 | IMNM | Rosett Max | CFO | S - Sale+OE | $21.92 | -65.0K | 54.0K | -55% | -$1.42M |
| DMT | 2026-04-03 19:46 | 2026-04-02 | IMNM | Rosett Max | CFO | M - OptEx | $0.00 | -71.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-02 | M | A | 31,848 | $1.05 | 79,324 | D | — | — | |
| 2 | Common | Common Stock | 2026-04-02 | M | A | 39,713 | $1.35 | 119,037 | D | — | — | |
| 3 | Common | Common Stock | 2026-04-02 | S | D | 63,656 | $21.91 | 55,381 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. (F2) The weighted average purchase price for the transaction report was $21.91, and the range of prices were between $21.44 and $22.44, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |
| 4 | Common | Common Stock | 2026-04-02 | S | D | 1,344 | $22.48 | 54,037 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. (F3) The weighted average purchase price for the transaction report was $22.48, and the range of prices were between $22.45 and $22.56, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |
| 5 | Derivative | Stock option (right to buy) | 2026-04-02 | M | D | 31,848 | $0.00 | 60,000 | D | $1.05 · — to 2033-03-22 | 31,848 Common Stock | (F4) The option is fully vested. |
| 6 | Derivative | Stock option (right to buy) | 2026-04-02 | M | D | 39,713 | $0.00 | 0 | D | $1.35 · — to 2032-03-23 | 39,713 Common Stock | (F4) The option is fully vested. |